Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider multiple factors when selecting an appropriate therapeutic. The primary goal of treatment is to improve patients’ quality of sleep, with minimal next-day side effects. While generics are entrenched in the treatment algorithm, the branded dual orexin receptor antagonists Belsomra (Merck) and Dayvigo (Eisai) provide a new mechanism of action for patients in later lines of therapy, and additional agents in the class are progressing through the pipeline or are poised to launch in the U.S. market. Therefore, understanding the use of current therapies among newly diagnosed and recently treated insomnia patients is essential to optimizing the uptake of branded therapies.
Geographies: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key drugs covered: Belsomra, Dayvigo, Edluar, Zolpimist, zolpidem IR, zolpidem CR, eszopiclone, trazodone, Rozerem, ramelteon, zaleplon, doxepin, benzodiazepines.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.